Phenotypes of patients with asymptomatic hyperuricemia living in the Russian Federation

Aim. To identify the phenotypes of patients with asymptomatic hyperuricemia (HU) in the Russian Federation by analyzing demographic and clinical and laboratory parameters in outpatient practice.

Material and methods. The data obtained in the framework of the non-interventional multicenter program “Assessment of epidemiological data on the detection of serum uric acid levels in patients with arterial hypertension, combined with metabolic syndrome, diabetes mellitus, and joint pain”, conducted in the Russian Federation, are presented. All study participants were examined according to the same single protocol.

Results. Asymptomatic HU was detected in every 10th patient, predominantly in women, every 2nd person worked, 1/3 of the persons had a higher education, the majority had a family. Among comorbidities, the most common were arterial 

hypertension (AH), coronary heart disease, osteoarthritis. In HU, the risk of AH was elevated more than 2-fold, atrial fibrillation (AF) – 3-fold, osteoarthritis – 2-fold. A direct correlation of HU with age (p = 0.004; r = 0.17), female sex (p = 0.001; r = 0.76), retired status (p = 0.002; r = 0.19), AH (p = 0.018; r = 0.18), AF (p = 0.007; r = 0.16), osteoarthritis (p = 0.032; r = 0.13) was determined. Association of HU with age (odds ratio (OR) 1.04; 95 % confidence interval (CI) 1.02–1.07; p = 0.002), retired status (OR 2.59; 95 % CI 1.35–3.77; p = 0.002), AH (OR 2.27; 95 % CI 1.13–4.53; p = 0.021), AF (OR 3.07; 95 % CI 1.31–7.20; p = 0.010), osteoarthritis (OR 1.90; 95 % CI 1.05–3.43; p = 0.033) was confirmed.

Conclusion. The phenotypes of patients with asymptomatic HU living in the Russian Federation were determined. An association of HU with a number of socio-demographic indicators, concomitant cardiovascular diseases, and osteoarthritis has been established.

1. Golovach I.Yu., Egudina E.D., Ter-Vartan’yan S.Kh. Asymptomatic hyperuricemia: hidden relationships, invisible effects and potential complications. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2020;58(6):725–33. (In Russ.). DOI: 10.47360/1995-4484-2020-725-733

2. Richette P., Doherty M., Pascual E. et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2016;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707

3. Hui M., Carr A., Cameron S. et al. The British Society for Rheumatology Guideline for the management of gout. Rheumatology (Oxford) 2017;56(7):e1–20. DOI: 10.1093/rheumatology/kex156

4. Pascart T., Latourte A., Flipo R.M. et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine 2020;87(5):395–404. DOI: 10.1016/j.jbspin.2020.05.002

5. Fitzgerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res (Hoboken) 2020;72(6):744–60. DOI: 10.1002/acr.24180

6. Waheed Y., Yang F., Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med 2021;36(6):1281–93. DOI: 10.3904/kjim.2020.340

7. Kuwabara M., Niwa K., Hisatome I. et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases. Hypertension 2017;69(6):1036–44. DOI: 10.1161/HYPERTENSIONAHA.116.08998

8. Valsaraj R., Singh A.K., Gangopadhyay K.K. et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr 2020;14(2):93–100. DOI: 10.1016/j.dsx.2020.01.007

9. Borghi C., Domienik-Karłowicz J., Tykarski A. et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J 2021;28(1):1–14. DOI: 10.5603/CJ.a2021.0001

10. Chazova I.E., Zhernakova Yu.V., Kislyak O.A. et al. Consensus on the description of patients with hyperuricemia and high cardiovascular risk: 2022. Sistemnye gipertenzii = Systemic Hypertension 2022;19(1):5–22. (In Russ.). DOI: 10.38109/2075-082X-2022-1-5-22

11. Shalnova S.A., Deev A.D., Artamonova G.V. et al. Hyperuricemia and its correlates in the russian population (results of the ESSE-RF epidemiological study). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2014;10(2):153–9. (In Russ.). DOI: 10.20996/1819-6446-2014-10-2-153-159

12. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

13. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

14. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

15. Taylor W.J., Fransen J., Jansen T.L. et al. Study for updated gout classification criteria: identification of features to classify gout. Arthritis Care Res (Hoboken) 2015;67(9):1304–15. DOI: 10.1002/acr.22585

16. Neogi T., Jansen T.L., Dalbeth N. et al. Gout classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 2015;74(10):1789–98. DOI: 10.1136/annrheumdis-2015-208237

17. Amirov N.B., Naumova A.Ya., Fatykhov R.G., Amirova R.N. Hyperuricemia: clinical consequences, cardiovascular risk, modern approach to therapy. Vestnik sovremennoy klinicheskoy meditsiny = Bulletin of Modern Clinical Medicine 2022;15(1):95–106 (In Russ.). DOI: 10.20969/VSKM.2022.15(1).95-106

18. Perez-Ruiz F., Marimon E., Chinchilla S.P. Hyperuricaemia with deposition: latest evidence and therapeutic approach. Ther Adv Musculoskeletal Dis 2015;7(6):225–33. DOI: 10.1177/1759720X15599734

19. Grayson P.C., Kim S.Y., LaValley M., Choi H.K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63(1):102–10. DOI: 10.1002/acr.20344

20. Cicero A.F., Salvi P., D’Addato S. et al. Brisighella Heart Study Group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens 2014;32(1):57–64. DOI: 10.1097/HJH.0b013e328365b916

21. Wheeler J.G., Juzwishin K.D., Eiriksdottir G. et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005;2(3):e76. DOI: 10.1371/journal.pmed.0020076

22. Yan L., Liu Z., Zhang C. Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis. Cell Biochem Biophys 2014;70(3):1597–601. DOI: 10.1007/s12013-014-0101-7

23. Chen Y., Xia Y., Han X. et al. Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China. BMJ Open 2017;7(12):e019037. DOI: 10.1136/bmjopen-2017-019037

24. Molchanova O.V., Britov A.N., Platonova E.V. Importance of elevated uric acid levels in the development and prevention of chronic non-communicable diseases. Profilakticheskaya meditsina = Preventive Medicine 2020;23(2):102–8. (In Russ.). DOI: 10.17116/profmed202023021102

25. Mantovani A., Rigolon R., Civettini A. et al. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. J Endocrinol Invest 2018;41(2):223–31. DOI: 10.1007/s40618-017-0729-4

26. Hidru T.H., Tang Y., Liu F. et al. Does serum uric acid status influence the association between left atrium diameter and atrial fibrillation in hypertension patients? Front Cardiovasc Med 2020;7:594788. DOI: 10.3389/fcvm.2020.594788

27. Bоrysenkо T.L., Snezhitskiy V.A., Kurbat M.N. et al. The correlation between hyperuricemia and structural and functional cardiac parameters in patients with hypertension and atrial fibrillation. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta = Journal of Grodno State Medical University 2022;20(2):187–96. (In Russ.). DOI: 10.25298/2221-8785-2022-20-2-187-196

28. Wang S., Pillinger M.H., Krasnokutsky S., Barbour K.E. The association between asymptomatic hyperuricemia and knee osteoarthritis: data from the third National Health and Nutrition Examination Survey. Osteoarthritis Cartilage 2019;27(9):1301–8. DOI: 10.1016/j.joca.2019.05.013

29. Ding X., Zeng C., Wei J. et al. The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. Rheumatol Int 2016;36(4):567–73. DOI: 10.1007/s00296-015-3418-7

30. Jonsson H., Aspelund T., Eiriksdottir G. et al. Hyperuricemia is associated with intermittent hand joint pain in a cross sectional study of elderly females: The AGES-Reykjavik Study. PLoS One 2019;14(8):e0221474. DOI: 10.1371/journal.pone.0221474

31. Rudenko I.B., Pashkina Е.O., Karimova G.A. Hyperuricemia in the practice of a hospital physician. Terapiya = Therapy 2025:(S2):164–5. (In Russ.).

32. Mazurov V.I., Bashkinov R.A., Gaydukova I.Z. Fonturenko A.Yu. The impact of asymptomatic hyperuricemia on the course of comorbid pathology in patients with osteoarthritis and the possibilities of its correction. RMZH = RMJ 2021;(7): 24–30. (In Russ.).

33. Mazurov V.I., Bashkinov R.A., Inamova O.V. et al. Treatment of osteoarthritis associated with asymptomatic hyperuricemia: results of a pilot study. Terapiya = Therapy 2023;9(1):132–44. (In Russ.). DOI: 10.18565/therapy.2023.1.132-144

34. Drapkina O.M., Mazurov V.I., Martynov A.I. et al. Consensus for physicians on the management of patients with asymptomatic hyperuricemia in general practice. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2024;23(1):3737. (In Russ.). DOI: 10.15829/1728-8800-2024-3737